Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $140.00 short put and a strike $135.00 long put offers a potential 16.28% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $140.00 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $4.30 would be incurred if the stock dropped below the $135.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 42.35 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
3 Sectors Holding Up Well Despite Market Selloffs
Tue, 10 Mar 2020 21:13:22 +0000
Companies in these industries have seen less bearish sentiment compared to the broader US market Continue reading…
Closely watched opioid trial in New York postponed due to coronavirus
Tue, 10 Mar 2020 18:59:40 +0000
The postponement of the March 20 jury trial was a precautionary measure due to the number of people traveling to attend, according to a spokesman for New York Attorney General Letitia James. A new trial was not set but a hearing will be held April 14 to decide next steps in the case, which is in state court in Suffolk County on New York's Long Island.
These nine companies are working on coronavirus treatments or vaccines — here’s where things stand
Tue, 10 Mar 2020 14:56:00 +0000
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
GSK's HIV combo treatment meets main goal in late-stage study
Mon, 09 Mar 2020 15:13:14 +0000
GlaxoSmithKline PLC's unit ViiV Healthcare said on Monday its two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month. The drug, Cabenuva, the long-acting injectable two-drug regimen of antiviral compounds cabotegravir and Johnson & Johnson's rilpivirine, met the main goal at the end of 48 weeks. “This two-drug regimen may provide an opportunity for people living with HIV to break the cycle of taking a daily pill and reduce their total treatment dosing days from 365 to six,” Kimberly Smith, head of research and development, said.
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
Fri, 06 Mar 2020 15:18:00 +0000
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
Also on Market Tamer…
Follow Us on Facebook